Literature DB >> 2454957

Tumour associated antigens in diagnosis of serous effusions.

J Mezger1, W Permanetter, A L Gerbes, W Wilmanns, R Lamerz.   

Abstract

The use of tumour associated antigens in the diagnosis of serous effusions was studied in 76 patients with benign and 200 patients with malignant disease. Tissue polypeptide antigen (TPA), alpha fetoprotein, and CA 125 were found to be of little value. At cut off points of 3 ng/ml, 10 U/ml, and 30 U/ml, respectively, carcinoembryonic antigen (CEA), biliary glycoprotein I (BGP I), and CA 19-9 discriminated between benign and malignant serous effusions with a sensitivity of between 24% and 67%. The immunocytochemical staining for these markers resulted in malignant cells being detected in 18% to 33% of cases. Various combinations of conventional cytological examination, effusion fluid tumour marker determination, and immunocytochemical analysis identified malignant cells in serous effusions in up to 72% of cases; conventional cytology alone detected tumour cells in only 30%.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2454957      PMCID: PMC1141543          DOI: 10.1136/jcp.41.6.633

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  52 in total

1.  Cancer-associated proteins in effusion fluids.

Authors:  S N Booth; G Lakin; P W Dykes; D Burnett; A R Bradwell
Journal:  J Clin Pathol       Date:  1977-06       Impact factor: 3.411

2.  Carcinoembryonic antigen titers on effusion fluid. A diagnostic tool?

Authors:  J S Nystrom; B Dyce; J Wada; J R Bateman; B Haverback
Journal:  Arch Intern Med       Date:  1977-07

3.  Diagnostic value of the estimation of glucose in ascitic fluid.

Authors:  M Polak; A C Torres da Costa
Journal:  Digestion       Date:  1973       Impact factor: 3.216

4.  Carcinoembryonic antigen (CEA) and related antigens in blood cells and hematopoietic tissues.

Authors:  M Bordes; S Knobel; F Martin
Journal:  Eur J Cancer       Date:  1975-11       Impact factor: 9.162

5.  Concurrent assays of plasma and pleural-effusion levels of carcinoembryonic antigen in the diagnosis of pulmonary disease.

Authors:  C F Stanford; A M Neville; D J Laurence
Journal:  Lancet       Date:  1978-07-01       Impact factor: 79.321

6.  Quantification of carcinoembryonic antigen-like activities in normal, human gastrointestinal secretions.

Authors:  V L Go; H V Ammon; K H Holtermuller; E Krag; S F Phillips
Journal:  Cancer       Date:  1975-12       Impact factor: 6.860

7.  [Determination of carcinoembryonic antigen (CEA) in patients with tumors of the large intestine. Experience with a new radioimmunoassay (author's transl)].

Authors:  R Lamerz; H Ruider
Journal:  MMW Munch Med Wochenschr       Date:  1976-03-19

8.  Carcinoembryonic antigen levels in benign and malignant pleural effusions.

Authors:  R A Rittgers; M S Loewenstein; A E Feinerman; H Z Kupchik; B R Marcel; R S Koff; N Zamcheck
Journal:  Ann Intern Med       Date:  1978-05       Impact factor: 25.391

9.  Carcinoembryonic antigen assay of ascites and detection of malignancy.

Authors:  M S Loewenstein; R A Rittgers; A E Feinerman; H Z Kupchik; B R Marcel; R S Koff; N Zamcheck
Journal:  Ann Intern Med       Date:  1978-05       Impact factor: 25.391

10.  Efficacy of prolonged intermittent therapy with combined 5-fluorouracil and methyl-CCNU following resection for carcinoma of the large bowel. A Veterans Administration Surgical Oncology Group report.

Authors:  G A Higgins; J H Amadeo; J McElhinney; J J McCaughan; R J Keehn
Journal:  Cancer       Date:  1984-01-01       Impact factor: 6.860

View more
  7 in total

1.  Value of carcinoembryonic antigen (CEA) and cholesterol assays of ascitic fluid in cases of inconclusive cytology.

Authors:  M Gulyás; A D Kaposi; G Elek; L G Szollár; A Hjerpe
Journal:  J Clin Pathol       Date:  2001-11       Impact factor: 3.411

2.  Value of serum and effusion fluid CEA levels for distinguishing between diffuse malignant mesothelioma and carcinomatous pleural metastases.

Authors:  J Mezger; A Calavrezos; P Drings; U Gatzemeier; E Kaukel; N Konietzko; G Koschel; R Lamerz; J von Pawel; W Römer
Journal:  Lung       Date:  1994       Impact factor: 2.584

3.  Tumor-associated antigens in effusions of malignant and benign origin.

Authors:  A Ammon; H Eiffert; S Reil; J H Beyer; M Droese; W Hiddemann
Journal:  Clin Investig       Date:  1993-06

4.  Distribution of radiolabelled anti-CA125 monoclonal antibody OC125-F(ab)2-fragment following resection guided by antibodies (REGAJ) in ovarian cancer patients.

Authors:  M M Uttenreuther-Fischer; H Feistel; F Wolf; W Jäger
Journal:  J Clin Lab Anal       Date:  1997       Impact factor: 2.352

5.  Measurement of placental alkaline phosphatase activity in benign and malignant pleural effusions.

Authors:  R J Fergusson; J Fisken; M A McIntyre; J E Roulston; R C Leonard
Journal:  J Clin Pathol       Date:  1992-12       Impact factor: 3.411

6.  The value of serum tumour markers in the prediction of aetiology and follow up of patients with pericardial effusion.

Authors:  U Bildirici; U Celikyurt; E Acar; O Bulut; T Sahin; G Kozdag; D Ural
Journal:  Cardiovasc J Afr       Date:  2012-04       Impact factor: 1.167

7.  Diagnostic Utility of Combined CEA, CA15-3 and CA125 Biomarkers and Cytomorphology in Suspicious and Malignant Serosal Fluid.

Authors:  Zahra Rahemi; Abdolreza Javadi; Behrang Kazeminejad; Abdolali Ebrahimi; Houman Vosough; Afsoon Taghavi; Shahriar Dabiri
Journal:  Iran J Pathol       Date:  2021-05-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.